Myriad Genetics, Inc.
MYGN Healthcare Diagnostics & Research
Myriad Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $824.5 million, down 1.56% from fiscal 2024. In the quarter to June 2026, revenue fell 10.5%, EPS grew 87.1%, free cash flow grew 43.9% and total debt rose 103.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow MYGN
Myriad Genetics, Inc. (MYGN) EV/Sales
As of 16 October 2026, Myriad Genetics, Inc. (MYGN) trades at a EV/Sales of 0.5×. Over the past ten years it has ranged from 0.4× (May 2025) to 4.5× (September 2018); the current reading is higher than 3% of that period. That is below the Diagnostics & Research industry median of 5.5× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.7× | (49.16%) |
| FY2024 | 1.4× | (27.68%) |
| FY2023 | 2.0× | 6.42% |
| FY2022 | 1.9× | (7.89%) |
| FY2022 | 2.0× | (26.93%) |
| FY2021 | 2.8× | (14.36%) |
| FY2021 | 3.2× | 32.18% |
| FY2020 | 2.4× | 79.68% |
| FY2020 | 1.4× | (47.99%) |
| FY2019 | 2.6× | 5.17% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.8× | 30.64% |
| Mar 2026 | 0.6× | (20.83%) |
| Dec 2025 | 0.7× | (15.12%) |
| Sep 2025 | 0.9× | 33.18% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MYGN Myriad Genetics, Inc. | 0.5× |
| FLGT Fulgent Genetics, Inc. compare | 1.0× |
| CSTL Castle Biosciences, Inc. compare | 2.0× |
| OPK OPKO Health, Inc. compare | 2.0× |
| BDSX Biodesix, Inc. compare | 2.5× |
| XGN Exagen Inc. compare | 2.6× |
| BNR Burning Rock Biotech Limited Sponsored ADR compare | 17.9× |
| PSNL Personalis, Inc. compare | 20.9× |
| MDXHF MedX Health Corp. compare | 29.4× |
| Diagnostics & Research industry median | 5.5× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)